Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4364 Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma

Introduction: Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Fojo T, Edgerly M, Pacak K, Figg W,

Keywords: PPGL, pheochromocytoma, paraganglioma, axitinib, TKI, tyrosinase kinase inhibitors,

#1864 Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status

Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. Prognostic factors currently included in the reference AJCC classification are mainly clinical.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Benhamou J, Deschamps L, Vergier B, Pham-Ledard A, Carlotti A,

Keywords: Merkel cell carcinoma, mTor, CXCR4, PD-L1,

#1377 Metastatic Neuro Endocrine Tumors: Epidemiological Characteristics, Management and Prognostics Factors. Results from an Inter-Regional Network in France between Upper and Lower Normandy

Introduction: Metastatic neuro-endocrine tumors (MNETs) are rare and their management are complex. To standardize therapeutic strategies in France, a national network of clinicians (RENATEN) has been created, composed of 17 expert centres.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lesouef M, Bouhier-Leporier K, Pham A, Granier S, Dupont B,

Keywords: Metastatic Neuro-Endocrine Tumors, Epidemiological Characteristics,

#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment

Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kiesewetter B, Koparek O, Mayerhoefer M, Niederle B, Raderer M,

Keywords: GI-NEC,

#744 Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs)

Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Holubec L

Authors: Holubec L, Finek J, Fiala O, Matejka V, Dreslerova J,

Keywords: GEP-NET, experimental metronomic therapy, tumor marker,